Current Oncology Reports

, Volume 12, Issue 6, pp 352–354 | Cite as

The Addition of Rituximab to Fludarabine and Cyclophosphamide Improves Progression-free Survival in Patients with Previously Treated Chronic Lymphocytic Leukemia

Clinical Trial Report
  • 81 Downloads

References

  1. 1.
    Dighiero G, Hamblin TJ: Chronic lymphocytic leukaemia. Lancet 2008, 371:1017–1029.CrossRefPubMedGoogle Scholar
  2. 2.
    Weiss MA, Maslak PG, Jurcic JG, et al.: Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 2003, 21:1278–1284.CrossRefPubMedGoogle Scholar
  3. 3.
    Eichhorst BF, Busch R, Hopfinger G, et al.: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006, 107:885–891.CrossRefPubMedGoogle Scholar
  4. 4.
    Tam CS, O’Brien S, Wierda W, et al.: Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112:975–980.CrossRefPubMedGoogle Scholar
  5. 5.
    Wierda W, O’Brien S, Wen S, et al.: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4070–4078.CrossRefPubMedGoogle Scholar
  6. 6.
    Lamanna N, Kalaycio M, Maslak P, et al.: Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006, 24:1575–1581.CrossRefPubMedGoogle Scholar
  7. 7.
    Lamanna N, Jurcic JG, Noy A, et al.: Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 2009, 27:491–497.CrossRefPubMedGoogle Scholar
  8. 8.
    Foon KA, Boyiadzis M, Land SR, et al.: Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009, 27:498–503.CrossRefPubMedGoogle Scholar
  9. 9.
    Robak T, Dmoszynska A, Solal-Celigny P, et al.: Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010, 28:1756–1765.CrossRefPubMedGoogle Scholar
  10. 10.
    Eichhorst BF, Busch R, Stilgenbauer S, et al.: First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009, 114:3382–3391.CrossRefPubMedGoogle Scholar
  11. 11.
    Hallek M, Fingerle-Rowson G, Fink AM, et al.: First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL study group [abstract 535]. Blood (ASH Annual Meeting Abstracts) 2009, 114:Abstract 535.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Kimmel Cancer CenterThomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations